GPI Presented Research

Featured Research

All
  • All
  • 2023
  • 2022
  • 2021
Brown Modern Fashion Trends 2002 Blog Banner

Explore the pinnacle of our contributions at ISPOR 2023 Our team presented five cutting-edge research posters that redefine the landscape of healthcare economics and market access. Each poster encapsulates a wealth of insights, innovations, and strategic perspectives crafted by our expert team at GPI. Our posters delve into key themes shaping the future of market…

Blog Banner for Website Content

Value-based price forecasting: an accurate method for orphan drugs?

AUTHOR(S)
Anstee K , Jao R

IMAS time horizon banner

Importance of time horizon and analogue selection for value-based pricing of cell and gene therapies

AUTHOR(S) Anstee K, Jao R

CGT image

Regulatory and reimbursement landscape for Cell and Gene Therapies across Europe

AUTHOR(S)
Beards E, Song X, Kodabuckus S

Untitled design (8)

Solving the Chinese puzzle: What determines reimbursement price in China?

AUTHOR(S)
Song X, Kodabuckus S, Patel P

MicrosoftTeams-image (14)

The relationship between value and price in the free-pricing period and post-assessment price in Germany, a case study in rheumatoid arthritis

AUTHOR(S)
Cigerli S, Anstee K, Patel P

RA

Suitability of value-based price forecasting in a crowded landscape: A case study in rheumatoid arthritis

AUTHOR(S)
Anstee K, Patel P

China NRDL

The National Pricing & Reimbursement Process in China, a 2021 update

The research looks into detail at The Chinese National Reimbursement Drug List (NRDL) and reforms that have resulted in changes to the reimbursement process and how new drugs are launched within the market.

medicare

List prices for Medicare negotiation-eligible medicines targeted by Build Back Better

GPI attended ISPOR last month, in Washington D.C, and had the opportunity to present three research abstracts, including “List prices for Medicare negotiation-eligible medicines targeted by Build Back Better drug pricing provisions estimated to be reduced by over 40% on average.”

Oncology

Forecasting Drug Price for Reimbursement By Utilizing a Value-Price Relationship

GPI attended ISPOR (May 22), in Washington D.C, and had the opportunity to present three research abstracts, including our drug price forecasting study, utilizing a value-price relationship

Value Assessment & Price Forecasting

Find out more about value assessment and price forecasting, and how GPI can optimise your pricing strategy with our award winning methodology GPI horizon

Find out more

Engage with us

Register your interest
in GPI solutions

Sign up for
GPI updates